Rani Therapeutics Holdings, Inc.
RANI
$0.508
-$0.0059-1.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -83.27% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -83.27% | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -83.27% | -- | |||
| SG&A Expenses | 2.80% | -2.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.71% | 4.01% | |||
| Operating Income | -6.84% | 4.70% | |||
| Income Before Tax | 18.98% | -23.58% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 18.98% | -23.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -19.20% | 14.08% | |||
| Net Income | 18.81% | -31.90% | |||
| EBIT | -6.84% | 4.70% | |||
| EBITDA | -7.14% | 4.87% | |||
| EPS Basic | 20.70% | -16.45% | |||
| Normalized Basic EPS | -232.14% | 67.91% | |||
| EPS Diluted | 20.70% | -16.45% | |||
| Normalized Diluted EPS | -232.14% | 67.91% | |||
| Average Basic Shares Outstanding | 2.39% | 13.26% | |||
| Average Diluted Shares Outstanding | 2.39% | 13.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||